111 related articles for article (PubMed ID: 29393032)
1. [Treatment of primary and recurrent ovarian cancer].
Rosendahl M; Mosgaard BJ; Steffensen KD
Ugeskr Laeger; 2018 Jan; 180(4):. PubMed ID: 29393032
[TBL] [Abstract][Full Text] [Related]
2. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL; Spirtos NM; Enserro D; Herzog TJ; Sabbatini P; Armstrong DK; Kim JW; Park SY; Kim BG; Nam JH; Fujiwara K; Walker JL; Casey AC; Alvarez Secord A; Rubin S; Chan JK; DiSilvestro P; Davidson SA; Cohn DE; Tewari KS; Basen-Engquist K; Huang HQ; Brady MF; Mannel RS
N Engl J Med; 2019 Nov; 381(20):1929-1939. PubMed ID: 31722153
[TBL] [Abstract][Full Text] [Related]
3. [Epithelial ovarian cancer].
Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.
Fanfani F; Monterossi G; Fagotti A; Gallotta V; Costantini B; Vizzielli G; Petrillo M; Carbone MV; Scambia G
Ann Surg Oncol; 2015 Feb; 22(2):649-54. PubMed ID: 25155399
[TBL] [Abstract][Full Text] [Related]
6. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
7. Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy.
Bland AE; Everett EN; Pastore LM; Andersen WA; Taylor PT
Int J Gynecol Cancer; 2008; 18(4):629-36. PubMed ID: 17986246
[TBL] [Abstract][Full Text] [Related]
8. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
9. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
10. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery.
Paik ES; Lee YY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
Aust N Z J Obstet Gynaecol; 2016 Dec; 56(6):639-647. PubMed ID: 27611447
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery in the management of ovarian cancer.
Schwartz PE
Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
[TBL] [Abstract][Full Text] [Related]
12. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
Munkarah A
Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
[No Abstract] [Full Text] [Related]
13. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
14. [Individualized treatment for ovarian cancer may become possible].
Kjölhede P; Dahm-Kähler P; Tholander B; Åvall Lundqvist E
Lakartidningen; 2015 Dec; 112():. PubMed ID: 26646960
[TBL] [Abstract][Full Text] [Related]
15. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
16. [Ⅰ. Secondary Cytoreductive Surgery for Platinum-Sensitive Recurrent Ovarian Cancer -Review and Consideration from Recent International Phase Ⅲ Trials].
Yabuno A; Hasegawa K
Gan To Kagaku Ryoho; 2021 Feb; 48(2):191-194. PubMed ID: 33597357
[No Abstract] [Full Text] [Related]
17. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
19. Surgery for recurrent ovarian cancer: Options and limits.
Sehouli J; Grabowski JP
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():88-95. PubMed ID: 27865654
[TBL] [Abstract][Full Text] [Related]
20. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer.
Park JY; Eom JM; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
J Surg Oncol; 2010 Apr; 101(5):418-24. PubMed ID: 20082350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
